No abstract available
Publication types
-
Letter
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal, Humanized / administration & dosage*
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Biomarkers / blood
-
Cholesterol, LDL / blood
-
Coronary Artery Disease / diagnostic imaging
-
Coronary Artery Disease / therapy*
-
Drug Therapy, Combination
-
Dyslipidemias / blood
-
Dyslipidemias / diagnosis
-
Dyslipidemias / drug therapy*
-
Fibrosis
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
-
PCSK9 Inhibitors
-
Percutaneous Coronary Intervention* / adverse effects
-
Percutaneous Coronary Intervention* / instrumentation
-
Plaque, Atherosclerotic*
-
Prospective Studies
-
Rosuvastatin Calcium / administration & dosage*
-
Rosuvastatin Calcium / adverse effects
-
Serine Proteinase Inhibitors / administration & dosage*
-
Serine Proteinase Inhibitors / adverse effects
-
Stents
-
Time Factors
-
Tomography, Optical Coherence
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Biomarkers
-
Cholesterol, LDL
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
PCSK9 Inhibitors
-
Serine Proteinase Inhibitors
-
Rosuvastatin Calcium
-
PCSK9 protein, human
-
alirocumab